Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Authors: Camacho R, Clotet B, De Luca A, Geretti AM, Grossman Z, Kaiser R, Prosperi M, Schmit JC, Sönnerborg A, Torti C, Van Wijngaerden E, Vercauteren J, Zazzi M, Beheydt G, Imbrechts S, Libin P, Vandamme AM, Van Laethem K
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061436

Clinically evaluating genotypic interpretation systems is essential to provide optimal guidance in designing potent individualized HIV-regimens. This study aimed at investigating the ability of the latest Rega algorithm to predict virological response on a short and longer period.
Read More

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Authors: Abecasis AB, Camacho RJ, Clotet B, De Luca A, Grossman Z, Schülter E, Snoeck J, Sönnerborg A, Struck D, Theys K, Torti C, Vandamme AM, Vercauteren J, Zazzi M
Journal: Antimicrobial Agents and Chemotherapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/23183438

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
Read More

HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Authors: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DMC, Vandamme AM, Vercauteren J, Wensing AMJ
Publication Year: 2013
Journal: Retrovirology
Link: http://www.retrovirology.com/content/10/1/7

Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.
Read More

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Authors: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, Coughlan S, Frentz D, Griskevicius A, Grossman Z, Hamouda O, Horban A, Jørgensen LB, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Van de Vijver DA, Van Wijngaerden E, Vercauteren J, Wensing AMJ
Publication Year: 2014
Journal: BMC Infectious Diseases
Link: http://www.biomedcentral.com/1471-2334/14/407

One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.
Read More

Patterns of Transmitted HIV drug resistance in Europe vary by risk group

Authors: Abecasis A, Albert J, Åsjö B, Balotta C, Bergin C, Beshkov D, Boucher C, Camacho R, Clotet B, Frentz D, Griskevicius A, Grossman Z, Hamouda O, Horban A, Jørgensen L, Kolupajeva T, Korn K, Kostrikis L, Kücherer C, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Programme AW, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, van de Vijver D, Vandamme AM, Vercauteren J
Publication Year: 2014
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094495

In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.
Read More

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Patterns of Transmitted HIV drug resistance in Europe vary by risk group

About GHTM

Contacts

Map